<DOC>
	<DOCNO>NCT00001058</DOCNO>
	<brief_summary>To compare efficacy safety clarithromycin combine rifabutin , ethambutol , treatment disseminate Mycobacterium avium Complex ( MAC ) disease person AIDS , include individual receive prior MAC prophylaxis . It believe effective therapy MAC disease patient AIDS require combination two antimycobacterial agent order overcome drug resistance unfavorable influence profound immunosuppression associate AIDS . Data suggest clarithromycin may substantial activity two- three-drug combination regimen clofazimine , rifamycin derivative , ethambutol , 4-quinolones .</brief_summary>
	<brief_title>A Comparison Three Drug Combinations Containing Clarithromycin Treatment Mycobacterium Avium Complex ( MAC ) Disease Patients With AIDS</brief_title>
	<detailed_description>It believe effective therapy MAC disease patient AIDS require combination two antimycobacterial agent order overcome drug resistance unfavorable influence profound immunosuppression associate AIDS . Data suggest clarithromycin may substantial activity two- three-drug combination regimen clofazimine , rifamycin derivative , ethambutol , 4-quinolones . Patients randomize one three treatment arm contain clarithromycin combination ethambutol , rifabutin , . Clarithromycin alone take day 1 3 determine tolerance rifabutin and/or ethambutol add day 3 . AS PER AMENDMENT 7/2/97 : Patients may elect add ritonavir indinavir treatment regimen . Treatment continue daily 48 week . In absence dose-limiting toxicity , patient determine complete partial responder continue regimen originally assign . Patients fail relapse originally assign MAC therapy , must therapy amend receive clarithromycin least two drug include originally assign regimen . Patients follow twice first week , every 2 week first 2 month , monthly next 4 month , every 2 month thereafter end 12 month . PER AMENDMENT 10/10/96 : NOTE : Any patient develops toxicity rifabutin ethambutol week 12 thereafter offer option register salvage regimen 2 new drug previously receive , plus clarithromycin continue study duration .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral therapy . Maintenance prophylactic therapy opportunistic infection ( exception specifically exclude drug ) . Carbamazepine theophylline . Isoniazid TB prophylaxis . PER AMENDMENT 10/10/96 : Therapy acute infectious process , MAC , provide patient stable therapy . Fluconazole therapy maintenance suppression fungal infection , provide patient stable dose least 4 week . PER AMENDMENT 7/02/97 : If patient elect receive indinavir , ORTHO/NOVUM 1/35 acceptable mean birth control . Patients must : HIV infection . Disseminated MAC disease . Life expectancy least 8 week . Consent parent guardian 18 year age . NOTE : This protocol approve prisoner participation . Prior Medication : Allowed : PER AMENDMENT 10/10/96 : Therapy acute infectious process , MAC , prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active mycobacterial infection MAC require treatment , exception isoniazid use solely TB prophylaxis . Concurrent Medication : Excluded : Other antimycobacterial drug ( exception isoniazid TB prophylaxis ) . Other investigational drug unless approve protocol chair . PER AMENDMENT 7/2/97 : For patient elect receive indinavir ritonavir : Terfenadine , astemizole , cisapride , triazolam , midazolam . For patient elect receive ritonavir : alprazolam , amiodarone , bepridil , bupropion , cisapride , clorazepate , clozapine , diazepam , dihydroergotamine , ergotamine , estazolam , encainide , flecainide , flurazepam , meperidine , pimozide , piroxicam , propafenone , propoxyphene , quinidine zolpidem . For patient elect receive indinavir : oral contraceptive ORTHO/NOVUM sole form birth control . For patient randomize rifabutincontaining arm : oral contraceptive Norplant sole form birth control . Patients follow prior condition exclude : History severe hypersensitivity erythromycin , clarithromycin , azithromycin , ethambutol , rifampin , rifabutin ( include Type 1 hypersensitivity reaction , StevensJohnson syndrome , hepatitis , optic neuritis , exfoliative dermatitis ) . Prior Medication : Excluded : Empiric presumptive antimycobacterial therapy prior study entry &gt; 14 day , within 90 day prior entry . NOTE : Patients unwilling discontinue presumptive therapy empiric therapy may enrol permission protocol chair , however , without MAC positive blood culture baseline , study medication discontinue ( AS PER AMENDMENT 7/2/97 ) . PER AMENDMENT 10/10/96 : Treatment clarithromycin ethambutol within 4 day initiation study medication . Treatment rifabutin rifampin within 7 day initiation study medication .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Rifabutin</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Ethambutol</keyword>
	<keyword>Clofazimine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Ciprofloxacin</keyword>
	<keyword>Clarithromycin</keyword>
</DOC>